Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study

Addition of ATX to ongoing cholinesterase-inhibitor therapy was generally well tolerated but did not significantly improve cognitive function.